BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 8844206)

  • 1. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.
    Eck SL; Alavi JB; Alavi A; Davis A; Hackney D; Judy K; Mollman J; Phillips PC; Wheeldon EB; Wilson JM
    Hum Gene Ther; 1996 Aug; 7(12):1465-82. PubMed ID: 8844206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group.
    Shand N; Weber F; Mariani L; Bernstein M; Gianella-Borradori A; Long Z; Sorensen AG; Barbier N
    Hum Gene Ther; 1999 Sep; 10(14):2325-35. PubMed ID: 10515452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors.
    Kun LE; Gajjar A; Muhlbauer M; Heideman RL; Sanford R; Brenner M; Walter A; Langston J; Jenkins J; Facchini S
    Hum Gene Ther; 1995 Sep; 6(9):1231-55. PubMed ID: 8527482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.
    Niranjan A; Moriuchi S; Lunsford LD; Kondziolka D; Flickinger JC; Fellows W; Rajendiran S; Tamura M; Cohen JB; Glorioso JC
    Mol Ther; 2000 Aug; 2(2):114-20. PubMed ID: 10947938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.
    Packer RJ; Raffel C; Villablanca JG; Tonn JC; Burdach SE; Burger K; LaFond D; McComb JG; Cogen PH; Vezina G; Kapcala LP
    J Neurosurg; 2000 Feb; 92(2):249-54. PubMed ID: 10659011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer.
    Hall SJ; Mutchnik SE; Chen SH; Woo SL; Thompson TC
    Int J Cancer; 1997 Jan; 70(2):183-7. PubMed ID: 9009158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.
    Trask TW; Trask RP; Aguilar-Cordova E; Shine HD; Wyde PR; Goodman JC; Hamilton WJ; Rojas-Martinez A; Chen SH; Woo SL; Grossman RG
    Mol Ther; 2000 Feb; 1(2):195-203. PubMed ID: 10933931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system.
    Culver KW; Van Gilder J; Link CJ; Carlstrom T; Buroker T; Yuh W; Koch K; Schabold K; Doornbas S; Wetjen B
    Hum Gene Ther; 1994 Mar; 5(3):343-79. PubMed ID: 8018748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.
    Xu F; Li S; Li XL; Guo Y; Zou BY; Xu R; Liao H; Zhao HY; Zhang Y; Guan ZZ; Zhang L
    Cancer Gene Ther; 2009 Sep; 16(9):723-30. PubMed ID: 19363470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technology evaluation: gene therapy (mesothelioma), NCI.
    Banerjee D
    Curr Opin Mol Ther; 1999 Aug; 1(4):517-20. PubMed ID: 11713768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.
    Germano IM; Fable J; Gultekin SH; Silvers A
    J Neurooncol; 2003 Dec; 65(3):279-89. PubMed ID: 14682378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
    Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
    Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.
    Oldfield EH; Ram Z; Culver KW; Blaese RM; DeVroom HL; Anderson WF
    Hum Gene Ther; 1993 Feb; 4(1):39-69. PubMed ID: 8384892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
    Westphal M; Ylä-Herttuala S; Martin J; Warnke P; Menei P; Eckland D; Kinley J; Kay R; Ram Z;
    Lancet Oncol; 2013 Aug; 14(9):823-33. PubMed ID: 23850491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.
    Vincent AJ; Vogels R; Someren GV; Esandi MC; Noteboom JL; Avezaat CJ; Vecht C; Bekkum DW; Valerio D; Bout A; Hoogerbrugge PM
    Hum Gene Ther; 1996 Jan; 7(2):197-205. PubMed ID: 8788170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
    Sterman DH; Treat J; Litzky LA; Amin KM; Coonrod L; Molnar-Kimber K; Recio A; Knox L; Wilson JM; Albelda SM; Kaiser LR
    Hum Gene Ther; 1998 May; 9(7):1083-92. PubMed ID: 9607419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
    Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
    Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
    Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study.
    Harsh GR; Deisboeck TS; Louis DN; Hilton J; Colvin M; Silver JS; Qureshi NH; Kracher J; Finkelstein D; Chiocca EA; Hochberg FH
    J Neurosurg; 2000 May; 92(5):804-11. PubMed ID: 10794295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.